key: cord-0031736-ah7c0rp2
authors: Van Meerbeke, Sara W; Fajt, Merritt L; Marini, Rachel V; Domsic, Robyn T; Petrov, Andrej A
title: Antibody Response to Graded Dosing of COVID-19 mRNA Vaccines After Allergic Reaction to First Dose
date: 2022-05-17
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2022.05.004
sha: 1b24f98206cdaed01a8eb059c268be7c0dd315ec
doc_id: 31736
cord_uid: ah7c0rp2

nan

In December 2020, an Emergency Use Authorization was issued for Pfizer-BioNTech and Moderna COVID-19 vaccines. Shortly thereafter, allergic reactions including anaphylaxis to vaccination were described. 1 Initial rates of anaphylaxis were reported at 11.1 cases per million doses administered. 2 Continued safety monitoring through the Vaccine Adverse Event Reporting System since then has shown lower rates of anaphylaxis. 3 While rare, systemic reactions have occurred, making administration of subsequent doses problematic in some patients, resulting in vaccine hesitancy. While single dose administration of second vaccination has been reported to be safe in patients with first dose immediate reaction, some patients decline this option. 4 Therefore, shared decision making about additional options for subsequent vaccination in these patients are needed. Here, we report a pilot study showing that graded COVID-19 mRNA vaccination is safe in patients with prior immediate allergic reactions and results in antibody titers comparable to healthy controls who received full dose vaccination.

We present data on eight patients with immediate reactions to first dose Pfizer-BioNTech and Moderna COVID-19 vaccines (4 from each vaccine) who underwent a graded second dose vaccination. This subset of patients represented ~15% of patients evaluated for COVID vaccine reaction at a University Allergy-Immunology clinic from December 2020 to February 2021.

Patient-reported symptoms after initial COVID-19 mRNA vaccination included cutaneous, oropharyngeal, respiratory, gastrointestinal, and hemodynamic changes (Table 1) SARS-COV-2 spike protein antibody levels were obtained approximately 6 months after graded dosing in 6 of the 8 patients, and the antibody levels were compared to a healthy control group matched by sex, age, and vaccine type ( Table 1 ). The study and control patients were tested by ELISA measuring IgG to SARS-COV2 spike protein using two different laboratories.

Study patient assays were performed through Quest Diagnostic and control patient assays were performed through Beckman Coulter. Statistical analysis was performed using JMP software (Cary, NC). Spike protein antibody levels were evaluated both qualitatively and quantitatively. controls. The authors of the study presented data as a log2 antibody response and antibody levels were checked at a minimum of 2 weeks after vaccination unlike our study where antibody response was checked at a minimum of 6 months after vaccination. 8

The limitations of our study include that the laboratory assays used were different between the 2 cohorts and antibody values may not be used interchangeably as per FDA expanded authorization of semiquantitative tests.

All patients with an immediate hypersensitivity reaction to COVID-19 vaccine should be referred to an allergy-immunology specialist. In patients hesitant to receive subsequent COVID- 

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine -United States

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Metaanalysis

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data